{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:35:35Z","timestamp":1791758135535,"version":"4.3.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks treatment options, with few evidence-based choices beyond lifestyle modification. This is the first clinical study to assess the efficacy of an organic liquid oral nutraceutical composed of turmeric extract, dandelion powder, milk thistle extract, and ginger powder in MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a randomized, double-blind, placebo-controlled, preliminary phase 2 exploratory trial conducted at a single center (Sanjivani Super Speciality Hospitals Pvt. Ltd., Gujarat, India) between September 7, 2021 and November 25, 2021. Individuals aged 18\u201370 years and diagnosed with fatty liver (grades 1\u20133) were eligible to participate. Participants were randomized 1:1 to receive the test product or placebo, which were both provided as a 60 mL oral solution to be consumed twice daily with a meal for 60 days. The primary endpoint was proportion of participants with improvement in ultrasonography-based fatty liver grading from baseline to Day 60.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifteen patients each were enrolled in the test product and placebo groups. The mean [standard deviation (SD)] age was 40.6 (10.8) years and 83.3% were male. A significantly higher proportion of patients in the nutraceutical product group had fatty liver grade improvement at Day 60 vs. placebo [60.0% (9\/15) vs. 13.3% (2\/15);\n                      <jats:italic>p<\/jats:italic>\n                      = 0.008]. Mean (SD) change in fatty liver grading was \u22120.60 (0.51) and \u22120.13 (0.35) for test product vs. placebo (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.007). Adverse events were mild with similar incidence in both groups. The results are limited by the small sample size, single-center design, and short study duration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study provides preliminary evidence that this organic nutraceutical may improve steatosis grade in individuals with MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>Clinical Trial Registry of India (CTRI\/2021\/08\/035359).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1761666","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:40:31Z","timestamp":1773326431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Helen","family":"Messier","sequence":"first","affiliation":[{"name":"Altum Medical","place":["Orlando, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Sanjivani Hospital","place":["Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Bhomia","sequence":"additional","affiliation":[{"name":"Sanjivani Hospital","place":["Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Kataria","sequence":"additional","affiliation":[{"name":"Sanjivani Hospital","place":["Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanashyam","family":"Patel","sequence":"additional","affiliation":[{"name":"Green Medic Solution","place":["Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2445780","DOI":"10.1080\/07853890.2024.2445780","article-title":"Research advances in the diagnosis and treatment of MASLD\/MASH","volume":"57","author":"Wang","year":"2025","journal-title":"Ann Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3904\/kjim.2018.309","article-title":"Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study","volume":"35","author":"Yoo","year":"2020","journal-title":"Korean J Intern Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology."},{"key":"B5","volume-title":"Fatty Liver","author":"Antunes","year":"2025"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of non-alcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.3390\/nu13124440","article-title":"Curcumin in metabolic health and disease","volume":"13","author":"Jabczyk","year":"2021","journal-title":"Nutrients."},{"key":"B8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.fct.2013.04.023","article-title":"Taraxacum official (dandelion) leaf extract alleviates high-fat diet-induced nonalcoholic fatty liver","volume":"58","author":"Davaatseren","year":"2013","journal-title":"Food Chem Toxicol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3109\/13880209.2015.1057651","article-title":"Ginger extract modulates Pb-induced hepatic oxidative stress and expression of antioxidant gene transcripts in rat liver","volume":"54","author":"Mohamed","year":"2016","journal-title":"Pharm Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6661937","DOI":"10.1155\/2021\/6661937","article-title":"6-Gingerol, a major ingredient of ginger attenuates diethylnitrosamine-induced liver injury in rats through the modulation of oxidative stress and anti-inflammatory activity","volume":"2021","author":"Alsahli","year":"2021","journal-title":"Mediators Inflamm."},{"key":"B11","volume-title":"Milk Thistle","author":"Achufusi","year":"2025"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3593951","DOI":"10.1155\/2016\/3593951","article-title":"The therapeutic effect of berberine in the treatment of nonalcoholic fatty liver disease: a meta-analysis","volume":"2016","author":"Wei","year":"2016","journal-title":"Evid Based Complement Alternat Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/07315724.2015.1021057","article-title":"Functions of coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by non-alcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial","volume":"35","author":"Farsi","year":"2016","journal-title":"J Am Coll Nutr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12933-024-02326-8","article-title":"Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial","volume":"23","author":"Vrentzos","year":"2024","journal-title":"Cardiovasc Diabetol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e72596","DOI":"10.7759\/cureus.72596","article-title":"Vitamin E and non-alcoholic fatty liver disease: investigating the evidence through a systematic review","volume":"16","author":"Abera","year":"2024","journal-title":"Cureus."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41430-023-01336-1","article-title":"Dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in U","volume":"77","author":"Chai","year":"2023","journal-title":"Eur J Clin Nutr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"20406223251358659","DOI":"10.1177\/20406223251358659","article-title":"The impact of choline supplementation on oxidative stress and clinical outcomes among patients with non-alcoholic fatty liver disease: a randomized controlled study","volume":"16","author":"Sedhom","year":"2025","journal-title":"Ther Adv Chronic Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3945\/an.114.007955","article-title":"Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes","volume":"7","author":"Sherriff","year":"2016","journal-title":"Adv Nutr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1039\/D4FO05847J","article-title":"Flaxseed powder supplementation in non-alcoholic fatty liver disease: a randomized controlled clinical trial","volume":"16","author":"Tian","year":"2025","journal-title":"Food Funct."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1721748","DOI":"10.1101\/2025.09.26.25336688","article-title":"Long-term safety and efficacy of a highly purified plant-based nutraceutical for improving clinical parameters of liver function in healthy participants: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Patel","year":"2025"},{"key":"B21","doi-asserted-by":"publisher","first-page":"818268","DOI":"10.3389\/fphar.2021.818268","article-title":"Levels and health risk of pesticide residues in Chinese herbal medicines","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e075840","DOI":"10.1136\/bmjopen-2023-075840","article-title":"Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA","volume":"13","author":"Lauffenburger","year":"2023","journal-title":"BMJ Open."},{"key":"B23","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/ar4524","article-title":"Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study","volume":"16","author":"Singh","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nutrit\/nuad166","article-title":"Curcumin supplementation effect on liver enzymes in patients with non-alcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials","volume":"83","author":"Vajdi","year":"2025","journal-title":"Nutr Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/ptr.6171","article-title":"Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases","volume":"32","author":"Abenavoli","year":"2018","journal-title":"Phytother Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e34897","DOI":"10.5812\/hepatmon.34897","article-title":"Ginger supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"16","author":"Rahimlou","year":"2016","journal-title":"Hepat Mon."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.fct.2010.03.037","article-title":"In vitro and in vivo hepatoprotective effects of the aqueous extract from Taraxacum officinale (dandelion) root against alcohol-induced oxidative stress","volume":"48","author":"You","year":"2010","journal-title":"Food Chem Toxicol."},{"key":"B28","unstructured":"FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH'\n          \n          2025"},{"key":"B29","unstructured":"FDA Approves First Treatment for Patients With Liver Scarring Due to Fatty Liver Disease\n          \n          2024"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","author":"Younossi","year":"2025","journal-title":"Gastroenterology"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1761666\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:40:37Z","timestamp":1773326437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1761666\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"alternative-id":["10.3389\/fnut.2026.1761666"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1761666","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1761666"}}